Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$268.3 - $380.31 $1.09 Million - $1.55 Million
-4,064 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$248.13 - $308.36 $8.71 Million - $10.8 Million
-35,104 Reduced 89.62%
4,064 $1.2 Million
Q3 2020

Nov 12, 2020

SELL
$215.51 - $272.51 $9.17 Million - $11.6 Million
-42,536 Reduced 52.06%
39,168 $10.3 Million
Q2 2020

Aug 14, 2020

SELL
$127.44 - $232.72 $3.52 Million - $6.43 Million
-27,634 Reduced 25.27%
81,704 $18.4 Million
Q1 2020

May 12, 2020

SELL
$108.83 - $165.23 $4.44 Million - $6.74 Million
-40,810 Reduced 27.18%
109,338 $14.4 Million
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $172,888 - $266,348
-1,622 Reduced 1.07%
150,148 $24.1 Million
Q3 2019

Nov 15, 2019

BUY
$113.31 - $150.51 $868,407 - $1.15 Million
7,664 Added 5.32%
151,770 $17.3 Million
Q2 2019

Aug 14, 2019

SELL
$115.0 - $141.58 $147,200 - $181,222
-1,280 Reduced 0.88%
144,106 $20.4 Million
Q1 2019

May 14, 2019

SELL
$98.85 - $134.59 $3.62 Million - $4.93 Million
-36,654 Reduced 20.14%
145,386 $18.2 Million
Q4 2018

Feb 13, 2019

BUY
$63.81 - $109.82 $42,178 - $72,591
661 Added 0.36%
182,040 $17.5 Million
Q3 2018

Nov 13, 2018

BUY
$75.5 - $96.63 $6.49 Million - $8.31 Million
85,960 Added 90.09%
181,379 $13.8 Million
Q2 2018

Aug 15, 2018

BUY
$74.84 - $100.16 $3.62 Million - $4.84 Million
48,319 Added 102.59%
95,419 $7.91 Million
Q1 2018

May 14, 2018

SELL
$56.95 - $85.19 $2.07 Million - $3.09 Million
-36,318 Reduced 43.54%
47,100 $3.79 Million
Q4 2017

Feb 12, 2018

BUY
$22.57 - $63.56 $1.88 Million - $5.3 Million
83,418
83,418 $5.27 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Granahan Investment Management, LLC Portfolio

Follow Granahan Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granahan Investment Management, LLC with notifications on news.